HIV/AIDS Progression
Timed ablation of regulatory CD4+ T cells prevents AIDS progression
Published in AIDS Weekly, June 21st, 2004
According to scientists from Australia, "Successful immunotherapy of murine AIDS (MAIDS) in C57BL/6J mice based on the elimination of replicating CD4+ regulator T cells" is described. "We demonstrate that a single injection of the antimitotic drug vinblastine (Vb) given 14 days postinfection (p.i.) with LP-BM5 can prevent MAIDS progression."
"Treatment with anti-CD4 mAb at 14 days p.i. is similarly able to prevent MAIDS. Treatment at other time points with Vb or anti-CD4 mAb is ineffective. The effect is based on ablation of a replicating dominantly suppressive CD4+ T cell...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2004-06-21)
More Articles from AIDS Weekly
- HIV/AIDS
Ezrin/CD95 linkage key role regulating susceptibility to CD95-mediated apoptosis - HIV/AIDS
Intracellularly expressed HIV-1 Tat protein inhibits neural cell proliferation - HIV/AIDS Treatment
Cell surface targets identified for HIV-1 therapeutics using genetic screens - Virology
Dendritic cell-associated function impairment distinguish HCV and HIV infection - AIDS Vaccine
Volunteers needed as more AIDS vaccines move into clinical trials - Anorexia
Megestrol acetate improves appetite and weight gain in cancer and AIDS patients - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
